Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alessandra Santomaggio
"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer
Clinical Colorectal Cancer
Oncology
Gastroenterology
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Sorafenib in Combination With Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-Line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Clinical Cancer Research
Cancer Research
Oncology
Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study
British Journal of Cancer
Cancer Research
Oncology
Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study
Tumori
Medicine
Cancer Research
Oncology
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
